ALK-Abelló Management

Mr. Peter Halling is President & CEO of ALK-Abelló A/S from 2023. Mr. Peter Halling serves as Chief Executive Officer at Fertin Pharma A/S since August 2020. He has an extensive experience from working in...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Claus Solje	Executive VP	less than a year	kr.14.86m	no data
Søren Niegel	Executive VP of Commercial Operations & Member of Management Board	12yrs	kr.6.51m	0.020% DKK 6.5m
Henriette Mersebach	Executive VP Research & Development & Member of Management Board	1.2yrs	kr.7.18m	no data
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	no data	kr.350.00k	no data
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	no data	kr.270.00k	no data
Peter Halling	President & CEO	1.3yrs	no data	no data
Per Plotnikof	VP of Corporate Communications	no data	no data	no data
Hendrik Kees Nolte	Senior Vice President of Research & Development - North America and International Markets	7.2yrs	no data	no data
Christian Houghton	Head of Product Supply	5.3yrs	no data	no data

3.3yrs

Average Tenure

52yo

Average Age

Experienced Management: ALK B's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	13.3yrs	kr.350.00k	no data
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	1.2yrs	kr.270.00k	no data
Jesper Hoiland	Independent Director	1.2yrs	kr.366.00k	no data
Lene Skole-Sorensen	Vice Chairman of the Board	10.3yrs	kr.900.00k	no data
Anders Hedegaard	Independent Chairman of the Board	4.2yrs	kr.1.33m	no data
Lars Holmqvist	Director	9.2yrs	kr.446.00k	no data
Gitte Aabo	Independent Director	3.2yrs	kr.523.00k	no data
Alan Main	Independent Director	2.2yrs	kr.450.00k	no data
Bertil Lindmark	Independent Director	3.2yrs	kr.500.00k	no data
Nanna Carlson	Employee Representative Director	5.2yrs	kr.350.00k	no data
Johan Smedsrud	Employee Representative Director	5.2yrs	kr.350.00k	no data

4.2yrs

Average Tenure

60yo

Average Age

Experienced Board: ALK B's board of directors are considered experienced (4.2 years average tenure).

ALK-Abelló Management

Management criteria checks 2/4

Key information

Recent management updates

Insider recently sold kr.9.0m worth of stock

Alk-Abelló A/S Announces Executive Changes

ALK Announces Management Changes

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Recent updates

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

Price target increased by 15% to kr.143

First quarter 2024 earnings released

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Insider recently sold kr.9.0m worth of stock

Price target increased by 7.8% to kr.121

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

Price target decreased by 7.3% to kr.109

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Price target decreased by 9.2% to kr.116

Investor sentiment deteriorates as stock falls 15%

New major risk - Share price stability

Alk-Abelló A/S Announces Executive Changes

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Price target decreased by 8.5% to kr.129

Investor sentiment deteriorates as stock falls 22%

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

ALK Announces Management Changes

Full year 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Price target decreased to kr.161

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Now 20% undervalued after recent price drop

ALK Begins Clinical Trial Of Its Slit-tablet For The Treatment Of Peanut Allergy

Now 21% undervalued

Alk-Abelló A/S Announces Executive Changes

First quarter 2022 earnings: Revenues exceed analyst expectations

Now 20% undervalued

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

We Think ALK-Abelló (CPH:ALK B) Can Manage Its Debt With Ease

Less than half of directors are independent

Estimating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Is Now The Time To Put ALK-Abelló (CPH:ALK B) On Your Watchlist?

ALK Expects to Submit Registration Application in China for its House Dust Mite (HDM) Sublingual Allergy Immunotherapy (Slit) Tablet Already in 2022